| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT.
Address correspondence and reprint requests to Dr. John C. Morris, Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 South Euclid Ave., St. Louis, MO 63110-1093.
Objective: To evaluate the efficacy and safety of metrifonate, an acetylcholinesterase inhibitor, in patients clinically diagnosed with probable Alzheimer's disease(AD) of mild to moderate severity.
Methods: A prospective, 36-week, multicenter, double-blind, randomized, parallel group study of metrifonate in probable AD patients, including a 2-week screening period, a 26-week double-blind treatment period, and a follow-up visit at 8 weeks post-treatment. A total of 24 ambulatory clinics in the United States in a variety of settings, including contract research organizations, public health facilities, and universities. Patients met diagnostic criteria for probable AD as defined by the work group of the National Institute for Neurological and Communicative Diseases and Stroke and the Alzheimer's Disease and Related Disorders Association. Patients had Mini-Mental State Examination (MMSE) scores of 10 to 26 and Ischemic Scores(Rosen Modification) of <4. A total of 408 patients were enrolled. Percentages of patients completing double-blind treatment were 88% and 79% in the placebo and metrifonate groups, respectively. Rates of discontinuation due to adverse events were 4% in the placebo group and 12% in the metrifonate group. Placebo or metrifonate was administered once daily. Metrifonate-treated patients received a loading dose of 100 to 180 mg based on weight (2.0 mg/kg) for 2 weeks, followed by a maintenance dose of 30 to 60 mg based on weight(0.65 mg/kg) for 24 weeks. Primary efficacy variables were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus). Secondary efficacy variables included the Neuropsychiatric Inventory (NPI), the Disability Assessment in Dementia, the Global Deterioration Scale (GDS), the ADAS-Noncognitive subscale (ADAS-Noncog), the MMSE, and the Clinician's Interview-Based Impression of Severity with Caregiver Input (CIBIS-plus). Outcome measures reflected changes from baseline at week 26 for all variables. Safety was assessed with incidences of premature termination, treatment-emergent events and mortality, and routine safety evaluations.
Results: After 26 weeks of metrifonate therapy, a 2.86-point treatment difference(p = 0.0001) was observed in the ADAS-Cog scores of the intent-to-treat AD patients. The treatment difference in the mean CIBIC-plus score at this time was 0.28 points (p = 0.0071). At week 26, treatment differences also were observed in the mean NPI total score(p = 0.0161). Analysis of the remaining secondary efficacy variables showed treatment differences that favored metrifonate but did not reach statistical significance. Metrifonate adverse events were predominantly mild in intensity. No hepatotoxicity was observed.
Conclusions: Metrifonate was safe and well-tolerated. It enhanced not only the cognitive and global function, but also the behavioral function of patients diagnosed with mild to moderate AD. Therefore, metrifonate appears to be useful in the symptomatic treatment of AD.
Received August 20, 1997. Accepted in final form February 16, 1998.
This article has been cited by other articles:
|
|
 |
|
  A. S. Chappell, C. Gonzales, J. Williams, M. M. Witte, R. C. Mohs, and R. Sperling AMPA potentiator treatment of cognitive deficits in Alzheimer disease Neurology, March 27, 2007; 68(13): 1008 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rozzini, B. V. Chilovi, E. Bertoletti, M. Conti, I. Delrio, M. Trabucchi, and A. Padovani Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. American Journal of Alzheimer's Disease and Other Dementias, February 1, 2007; 22(1): 42 - 47. [Abstract] [PDF]
|
|
|
|
|
|
K. R. Peters, K. Rockwood, S. E. Black, R. Bouchard, S. Gauthier, D. Hogan, A. Kertesz, I. Loy-English, B. L. Beattie, A. D. Sadovnick, et al. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics Neurology, February 28, 2006; 66(4): 523 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Rankin and R. D. Layne The Use of Olanzapine in the Treatment of Negative Symptoms in Alzheimer's Disease J Neuropsychiatry Clin Neurosci, August 1, 2005; 17(3): 423 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Rockwood Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H.S. Silverman Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging J. Nucl. Med., April 1, 2004; 45(4): 594 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Cummings, L. Schneider, P. N. Tariot, P. R. Kershaw, and W. Yuan Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease Am J Psychiatry, March 1, 2004; 161(3): 532 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Bassiony and C. G. Lyketsos Delusions and Hallucinations in Alzheimer's Disease: Review of the Brain Decade Psychosomatics, October 1, 2003; 44(5): 388 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Anand, R. Hartman, H. Sohn, J. Danyluk, and S. M. Graham Impact of Study Design and Patient Population on Outcomes From Cholinesterase Inhibitor Trials Am J Geriatr Psychiatry, April 1, 2003; 11(2): 160 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.-H. Trinh, J. Hoblyn, S. Mohanty, and K. Yaffe Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis JAMA, January 8, 2003; 289(2): 210 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Tractenberg, M. F. Weiner, M. B. Patterson, A. Gamst, and L. J. Thai Emergent Psychopathology in Alzheimer's Disease Patients Over 12 Months Associated with Functional, Not Cognitive, Changes J Geriatr Psychiatry Neurol, June 1, 2002; 15(2): 110 - 117. [Abstract] [PDF]
|
|
|
|
|
|
D. H.S. Silverman, S. S. Gambhir, H.-W. C. Huang, J. Schwimmer, S. Kim, G. W. Small, J. Chodosh, J. Czernin, and M. E. Phelps Evaluating Early Dementia With and Without Assessment of Regional Cerebral Metabolism by PET: A Comparison of Predicted Costs and Benefits J. Nucl. Med., February 1, 2002; 43(2): 253 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Rockwood, J Mintzer, L Truyen, T Wessel, and D Wilkinson Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial J. Neurol. Neurosurg. Psychiatry, November 1, 2001; 71(5): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Cummings, A. Nadel, D. Masterman, and P. A. Cyrus Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease J Geriatr Psychiatry Neurol, June 1, 2001; 14(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
|
|
K. R. Daffner, D.M. Rentz, L. F.M. Scinto, R. Faust, A. E. Budson, and P. J. Holcomb Pathophysiology underlying diminished attention to novel events in patients with early AD Neurology, May 22, 2001; 56(10): 1377 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 8, 2001; 56(9): 1154 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Power, M. M. Oh, and J. F. Disterhoft Metrifonate Decreases sIAHP in CA1 Pyramidal Neurons In Vitro J Neurophysiol, January 1, 2001; 85(1): 319 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. GIACOBINI Cholinesterase Inhibitors Stabilize Alzheimer's Disease Ann. N.Y. Acad. Sci., December 1, 2000; 920(1): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Demers, M. Oremus, A. Perrault, and C. Wolfson Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Introduction J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 161 - 168. [Abstract] [PDF]
|
|
|
|
|
|
A. Perrault, M. Oremus, L. Demers, S. Vida, and C. Wolfson Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 181 - 196. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Raskind, E. R. Peskind, T. Wessel, and W. Yuan Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension Neurology, June 27, 2000; 54(12): 2261 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Tariot, P. R. Solomon, J. C. Morris, P. Kershaw, S. Lilienfeld, and C. Ding A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology, June 27, 2000; 54(12): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Paulsen, D. P. Salmon, L. J. Thal, R. Romero, C. Weisstein-Jenkins, D. Galasko, C. R. Hofstetter, R. Thomas, I. Grant, and D. V. Jeste Incidence of and risk factors for hallucinations and delusions in patients with probable AD Neurology, May 23, 2000; 54(10): 1965 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gelinas, S. Gauthier, and PamelaA. Cyrus Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living J Geriatr Psychiatry Neurol, April 1, 2000; 13(1): 9 - 16. [Abstract] [PDF]
|
|
|
|
 |
|
 N. C. Fox, S. Cousens, R. Scahill, R. J. Harvey, and M. N. Rossor Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease: Power Calculations and Estimates of Sample Size to Detect Treatment Effects Arch Neurol, March 1, 2000; 57(3): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. van Dyck, P. Newhouse, W. E. Falk, J. A. Mattes, and for the Physostigmine Study Group Extended-Release Physostigmine in Alzheimer Disease: A Multicenter, Double-blind, 12-Week Study With Dose Enrichment Arch Gen Psychiatry, February 1, 2000; 57(2): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Thal, M. Forrest, H. Loft, and H. Mengel Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease Neurology, January 25, 2000; 54(2): 421 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Farlow, P. A. Cyrus, A. Nadel, D. K. Lahiri, A. Brashear, and B. Gulanski Metrifonate treatment of AD: Influence of APOE genotype Neurology, December 1, 1999; 53(9): 2010 - 2010. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Mayeux and M. Sano Treatment of Alzheimer's Disease N. Engl. J. Med., November 25, 1999; 341(22): 1670 - 1679. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Mega, D. M. Masterman, S. M. O'Connor, T. R. Barclay, and J. L. Cummings The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease Arch Neurol, November 1, 1999; 56(11): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T BABIC;, P. T FRANCIS, A. M PALMER, M. SNAPE, and G. K WILCOCK The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 558 - 558. [Full Text] [PDF]
|
|
|
|
|
|
B. M. McLendon and P. M. Doraiswamy Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience J Geriatr Psychiatry Neurol, April 1, 1999; 12(1): 39 - 48. [Abstract] [PDF]
|
|
|
|
|
|
L. J. Thal, J. M. Ferguson, J. Mintzer, A. Raskin, and S. D. Targum A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease Neurology, April 1, 1999; 52(6): 1146 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Oh, J. M. Power, L. T. Thompson, P. L. Moriearty, and J. F. Disterhoft Metrifonate Increases Neuronal Excitability in CA1 Pyramidal Neurons from Both Young and Aging Rabbit Hippocampus J. Neurosci., March 1, 1999; 19(5): 1814 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Imbimbo, P. Martelli, W. M. Troetel, F. Lucchelli, U. Lucca, and L. J. Thal Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease Neurology, March 1, 1999; 52(4): 700 - 700. [Abstract] [Full Text]
|
|
|
|
|
|
P. T Francis, A. M Palmer, M. Snape, and G. K Wilcock The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry, February 1, 1999; 66(2): 137 - 147. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Sandson and D. Knopman Metrifonate for Alzheimer's disease: Is the next cholinesterase inhibitor better? Neurology, February 1, 1999; 52(3): 673 - 673. [Full Text]
|
|
|
|
 |
|
 R. Luckmann Metrifonate was effective in mild to moderate Alzheimer's disease Evid. Based Ment. Health, November 1, 1998; 1(4): 116 - 116. [Full Text]
|
|
|
|
|
|
D. Knopman, J. Kahn, and S. Miles Clinical Research Designs for Emerging Treatments for Alzheimer Disease: Moving Beyond Placebo-Controlled Trials Arch Neurol, November 1, 1998; 55(11): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rao and C. G. Lyketsos Delusions in Alzheimer's Disease: A Review J Neuropsychiatry Clin Neurosci, November 1, 1998; 10(4): 373 - 382. [Abstract] [Full Text]
|
|
|
|
 |
|
 Metrifonate Improves Cognitive Function in AD Journal Watch Psychiatry, August 1, 1998; 1998(801): 10 - 10. [Full Text]
|
|
|
|
 |
|
 Another Cholinesterase Inhibitor for Alzheimer's Disease Journal Watch (General), June 16, 1998; 1998(616): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
